Oral Anticoagulation and the Incidence of Stroke Associated with Atrial Fibrillation in Mainland Portugal: A Modelling Study
DOI:
https://doi.org/10.20344/amp.19255Keywords:
Anticoagulants/therapeutic use, Atrial Fibrillation/complications, Portugal, Stroke/prevention & controlAbstract
Introduction: Atrial fibrillation is the most prevalent persistent dysrhythmia, contributing to a significant social and economic burden. The main objective of this study was to evaluate the association between oral anticoagulant use and the incidence of stroke associated with atrial fibrillation, in mainland Portugal.
Methods: The number of episodes of inpatient care with a main diagnosis of stroke and an additional diagnosis of atrial fibrillation, occurring monthly between January 2012 and December 2018, in individuals aged 18 years or over, was extracted from the hospital morbidity database. The number of patients with an atrial fibrillation code documented in this database was used as a proxy for the prevalence of known atrial fibrillation. The number of anticoagulated patients was estimated from total medicine sales of vitamin K antagonists and novel oral anticoagulants (apixaban, dabigatran, edoxaban and rivaroxaban) in mainland Portugal. Descriptive analyses were performed, and seasonal autoregressive integrated moving average (SARIMA) models were built using the R software.
Results: The mean number of episodes of stroke per month was 522 (± 57). The number of anticoagulated patients increased gradually from 68 943 to 180 389 per month. The decreasing trend in the number of episodes has been observed since 2016, along with the increased use of new oral anticoagulants compared to vitamin K antagonists. The final model indicated that the increase in oral anticoagulation use between 2012 and 2018, in mainland Portugal, was associated with a decrease in the number of episodes of stroke associated with atrial fibrillation. It was estimated that the shift in the type of anticoagulation used, between 2016 and 2018, was associated with a reduction of 833 episodes of stroke in patients with atrial fibrillation (4.2%).
Conclusion: The use of oral anticoagulation was associated with a reduced incidence of stroke in patients with atrial fibrillation in mainland Portugal. This reduction was more relevant in the period between 2016 and 2018, and is probably related with the introduction of the novel oral anticoagulants.
Downloads
References
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373-498. DOI: https://doi.org/10.1093/eurheartj/ehaa612
Gouveia M, Costa J, Alarcão J, Augusto M, Caldeira D, Pinheiro L, et al. Carga e custo da fibrilhação auricular em Portugal. Rev Port Cardiol. 2015;34:1-11. DOI: https://doi.org/10.1016/j.repc.2014.08.005
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991;22:983-8. DOI: https://doi.org/10.1161/01.STR.22.8.983
Instituto Nacional de Estatística. Estatísticas da Saúde: 2018. 2018. [consultado 2020 out 19]. Disponível em: https://www.ine.pt/xurl/pub/257793024.
Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner, SJ, et al. The changing landscape for stroke prevention in AF: findings from the gloria-AF registry phase 2. J Am Coll Cardiol. 2017;69:777-85. DOI: https://doi.org/10.1016/j.jacc.2016.11.061
Silva Pinto S, Teixeira A, Henriques TS, Monteiro H, Martins C. AF-React study: atrial fibrillation management strategies in clinical practice - retrospective longitudinal study from real-world data in Northern Portugal. BMJ Open. 2021;11:e040404. DOI: https://doi.org/10.1136/bmjopen-2020-040404
Gomes E, Campos R, Morais R, Fernandes M. Estudo FATA: Prevalência de fibrilhação auricular e terapêutica antitrombótica nos cuidados de saúde primários de um concelho do norte de portugal. Acta Med Port. 2015;28:35. DOI: https://doi.org/10.20344/amp.5503
Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154-62. DOI: https://doi.org/10.1016/S0140-6736(14)61774-8
Chamberlain AM, Brown RD, Alonso A, Gersh BJ, Killian JM, Weston SA, et al. No decline in the risk of stroke following incident atrial fibrillation since 2000 in the community: a concerning trend. J Am Heart Assoc. 2016;5:e003408. DOI: https://doi.org/10.1161/JAHA.116.003408
Cowan JC, Wu J, Hall M, Orlowski A, West RM, Gale CP. A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018;39:2975-83. DOI: https://doi.org/10.1093/eurheartj/ehy411
Administração Central do Sistema de Saúde IP (ACSS). Base de dados de Morbilidade Hospitalar, 2012-2018. Lisboa: ACS; 2018.
Bonhorst D, Mendes M, De Sousa J, Primo J, Adragão P, Andrade S, et al. Prevalence of atrial fibrillation in the Portuguese population aged 40 and over: the FAMA study. Rev Port Cardiol. 2010;29:1207-17.
Primo J, Gonçalves H, Macedo A, Russo P, Monteiro T, Guimarães J, et al. Prevalence of paroxysmal atrial fibrillation in a population assessed by continuous 24-hour monitoring. Rev Port Cardiol. 2017;36:535-46. DOI: https://doi.org/10.1016/j.repce.2016.11.013
Monteiro P. The SAFIRA study: a reflection on the prevalence and treatment patterns of atrial fibrillation and cardiovascular risk factors in 7500 elderly subjects. Rev Port Cardiol. 2018;37:307-13. DOI: https://doi.org/10.1016/j.repce.2017.08.006
Hyndman RJ, Khandakar Y. Automatic time series forecasting: the forecast package for R. J Stat Softw. 2008;27:1-22. DOI: https://doi.org/10.18637/jss.v027.i03
Jespersen SF, Christensen LM, Christensen A, Christensen H. Increasing rate of atrial fibrillation from 2003 to 2011 in patients with ischaemic stroke: results from 55 551 patients in a nationwide registry. Eur J Neurol. 2015;22:839-44. DOI: https://doi.org/10.1111/ene.12671
Santos JV, Pereira J, Pinto R, Castro PM, Azevedo E, Freitas A. Atrial fibrillation as an Ischemic stroke clinical and economic burden modifier: a 15-year nationwide study. Value Heal. 2017;20:1083-91. DOI: https://doi.org/10.1016/j.jval.2017.04.018
Forslund T, Komen JJ, Andersen M, Wettermark B, Von Euler M, Mantel-Teeuwisse AK, et al. Improved stroke prevention in atrial fibrillation after the introduction of non-vitamin k antagonist oral anticoagulants: the Stockholm experience. Stroke. 2018;49:2122-8. DOI: https://doi.org/10.1161/STROKEAHA.118.021990
Yafasova A, Fosbøl EL, Christiansen MN, Vinding NE, Andersson C, Kruuse C, et al. Time trends in incidence, comorbidity, and mortality of ischemic stroke in Denmark (1996–2016). Neurology. 2020;95:e2343-53. DOI: https://doi.org/10.1212/WNL.0000000000010647
Christensen AL, Rasmussen LH, Baker MG, Lip GY, Dethlefsen C, Larsen TB. Seasonality, incidence and prognosis in atrial fibrillation and stroke in Denmark and New Zealand. BMJ Open. 2012;2:e001210. DOI: https://doi.org/10.1136/bmjopen-2012-001210
Loomba RS. Seasonal variation in paroxysmal atrial fibrillation: a systematic review. J Atr Fibrillation. 2015;7:9-14.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
